Gilead Sciences is investing $250m in LEO Pharma’s preclinical small molecules. According to the deal, Gilead will develop oral versions of the potential inflammation drugs, while Denmark’s LEO will focus on topical versions. Additional payments of up to $1.7bn could go to LEO, depending on the research’s progress. The molecules are being developed to target IL-4 and IL-13 proteins, known to be linked to inflammation.
What Is Banshee Stealer? This Advanced Malware Targets macOS Users, Steals Sensitive Data
A sophisticated version of Banshee Stealer malware has been secretly targeting macOS users for months, undetected while stealing personal data. The malware was first surfaced